CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 日期：二零二六年 月 日 股東簽署 （附註e、f、g、h及i） 本人╱吾等 （附註a） 地址為 為本公司股本中每股面值0.10港元之股份 股 （附註b） 之登記持有人，茲委任 （附註c） 大會主席或 ， 地址為 為本人╱吾等之代表 （附註c） ，代表本人╱吾等出席大會及其任何續會，並代表本人╱吾等依照下列指示投票。 本人╱吾等之投票意願如下：（請於合適之空欄內填上「✓」號 （附註d） ） 除另有界定者外，本通告所用詞彙與日期為二零二六年一月二十二日之召開大會通告（「通告」）所界定者具有相同 涵義。 | | 普通決議案# | 贊成 | 反對 | | --- | --- | --- | --- | | 1. | 批准認購協議、發行可轉換債券及授予董事會特別授權以配發及發行換 | | | | | 股股份。 | | | # 決議案全文載於通告。 收集個人資料聲明 中國生物科技服務控股有限公司（「本公司」）股東（「股東」）在本公司於二零 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 股東特別大會通告 茲通告中國生物科技服務控股有限公司（「本公司」）謹訂於二零二六年二月五日（星 期四）下午二時三十分假座香港銅鑼灣告士打道255–257號信和廣場19樓1904–05A 室舉行股東特別大會（「大會」），以通過下列事項︰ 普通決議案 承董事會命 中國生物科技服務控股有限公司 主席兼執行董事 劉小林 香港，二零二六年一月二十二日 註冊辦事處： Clarendon House 2 Church Street Hamilton HM 11 Bermuda 1 1. 「動議： (a) 謹此批准、確認及追認本公司（作為發行人）與富策控股有限公司（「認 購人」）（作為認購人）就認購人認購本金總額為35,000,000美元 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之持牌證券交易商、銀行經理、 律師、專業會計師或其他專業顧問。 閣下如已將名下之中國生物科技服務控股有限公司股份全部售出或轉讓，應立即將本通函及隨附 之代表委任表格送交買主或承讓人，或經手買賣或轉讓之銀行、持牌證券交易商或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） (1)建議根據特別授權發行可轉換債券； 及 (2)股東特別大會通告 本公司訂於二零二六年二月五日（星期四）下午二時三十分假座香港銅鑼灣告士打道255–257號信 和廣場19樓1904–05A室舉行股東特別大會，召開股東特別大會之通告載於本通函第SGM-1至 SGM-3頁。隨本通函附奉供股東 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 有關實施行動計劃以解決無法表示審計意見之季度更新 中國生物科技服務控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董 事（「董事」）會（「董事會」）謹此就有關解決本公司核數師對截至二零二四年十二月 三十一日止年度本集團綜合財務報表所作有關持續經營的無法表示意見（「無法表 示意見」）的行動計劃（「行動計劃」）實施情況提供季度更新。除非文義另有所指， 否則本公告所用詞彙與本公司截至二零二四年十二月三十一日止年度的年報所用 者具有相同涵義。 (1) 進行中的集資活動 誠如本公司日期為二零二五年十二月二十九日之公告內所披露，本公司已有 條件同意發行本金總額為35,000,000美元（相等於約272,300,000港元）之 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 就股東特別大會暫停辦理股份過戶登記手續之期間 謹此提述中國生物科技服務控股有限公司（「本公司」）日期為二零二五年十二月 二十九日之公告（「該公告」），內容有關（其中包括）建議根據特別授權發行可轉換 債券。除另有說明者外，於本公告內所採用之詞彙與該公告內所界定者具有相同 涵義。 本公司將會於適當時候將通函、股東特別大會通告及有關代表委任表格發送予股東。 承董事會命 中國生物科技服務控股有限公司 主席兼執行董事 劉小林 香港，二零二六年一月十九日 於本公告日期，董事會包括四名執行董事，即劉小林先生（主席）、何詢先生、 黃嵩先生及尹燁博士；及三名獨立非執行董事，即鄢國祥先生、郭圓濤博士及 張曉博士。 董事會謹此宣佈，本公司將於二 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | FF301 ...

Core Insights - The announcement of a strategic investment by Mr. Gong Hongjia, a prominent figure in the investment and industry sectors, marks a significant milestone for China Biotechnology Services (08037), as it plans to issue $35 million (approximately HKD 272 million) in convertible bonds, indicating a strong signal of confidence in the industry and resource integration value beyond mere financial injection [1][2][8] Group 1: Strategic Investor Entry - Mr. Gong Hongjia is recognized for his extensive experience in the healthcare and telecommunications sectors, having created several industry benchmarks and ranked 29th on the 2022 Forbes China Rich List [2] - His investment philosophy emphasizes "patient capital," which supports long-term enterprise development, exemplified by his successful angel investment in Hikvision [2][3] Group 2: Business Alignment and Synergy - Mr. Gong's strategic investment aligns closely with China Biotechnology Services' focus on BNCT (Boron Neutron Capture Therapy) and its comprehensive strategy involving detection services, CAR-T cell therapy, and BNCT, creating a strong complementary resource base [3][4] - The investment is seen as a deep recognition of the company's business layout, development stage, and core technology value, forming a "golden combination" of critical phases, investors, and business focus [3][4] Group 3: BNCT Technology and Market Dynamics - The investment highlights Mr. Gong's focus on the advancements in BNCT, a leading cancer radiotherapy technology known for its precision targeting and minimal side effects, which has shown significant potential in clinical applications [4][5] - The establishment of the Pengbo (Hainan) BNCT Hospital is a key initiative for capturing the BNCT market, with plans to commence patient treatment in early 2026, following the successful acquisition of advanced BNCT treatment systems [5][6] Group 4: Policy and Market Drivers - The strategic partnership coincides with a favorable period for the BNCT industry, characterized by supportive policies and increasing market demand, as the technology has been prioritized for expedited approval by regulatory authorities [6] - The rising cancer incidence and the urgent need for precise treatment solutions position BNCT as a promising innovation, with China Biotechnology Services leveraging its first-mover advantage and advanced equipment to establish significant industry barriers [6][7] Group 5: Future Outlook - The collaboration with Mr. Gong is expected to catalyze a second growth phase for China Biotechnology Services, breaking previous development bottlenecks and enhancing the integration of industry resources [8] - With ongoing policy support and rapid market growth, the company aims to deepen its strategic layout centered on BNCT, accelerating the industrialization of technology and the integration of services [8]

Core Viewpoint - The announcement of a strategic investment by Mr. Gong Hongjia through the issuance of a $35 million convertible bond marks a significant milestone for China Biotechnology Services, indicating a strong partnership that will enhance the company's core business and industry chain layout [1][8]. Group 1: Strategic Investor Entry - Mr. Gong Hongjia is a prominent figure in the investment and industry sectors, known for his deep insights in healthcare and telecommunications, and has a successful track record, including angel investment in Hikvision [2]. - His investment philosophy emphasizes "patient capital," which supports long-term enterprise development, further enhancing the credibility of the investment [2]. Group 2: Core Business Alignment - The strategic investment focuses on China Biotechnology Services' advancements in BNCT (Boron Neutron Capture Therapy), a leading cancer radiotherapy technology with significant clinical potential [4][5]. - The establishment of the Pengbo (Hainan) BNCT Hospital is a key initiative to capture the BNCT market, with plans to begin patient treatment in early 2026 [5]. Group 3: Policy and Market Drivers - The partnership coincides with a favorable policy environment for the BNCT industry, as it has been prioritized for expedited approval by the National Medical Products Administration and included in the "14th Five-Year Plan" as a key emerging industry [6]. - The increasing cancer incidence and demand for precise treatment solutions position BNCT as a promising market opportunity, with China Biotechnology Services leveraging its first-mover advantage in Hainan [6]. Group 4: Summary and Outlook - The collaboration with Mr. Gong Hongjia represents a transformative event for China Biotechnology Services, facilitating a breakthrough in development bottlenecks and initiating a second growth phase [8]. - The company aims to capitalize on policy benefits and market demand, focusing on BNCT technology and synergizing with Mr. Gong's enterprises to enhance its strategic layout and achieve significant growth [8].

Group 1 - The company has entered into a subscription agreement with Fucai Holdings to issue convertible bonds totaling $35 million (approximately HKD 272.3 million) [1] - The initial conversion price is set at HKD 0.66 per share, which could lead to the issuance of up to 412.6 million shares, representing approximately 42.28% of the total shares currently issued [1] - If the conversion rights are fully exercised, the total issued share capital will increase by approximately 29.72%, assuming no changes in the company's issued capital from the announcement date until conversion [1] Group 2 - The board believes that the subscription will strengthen the company's capital base and prepare for long-term development and improved financial status [2] - Issuing convertible bonds will not cause immediate dilution of existing shareholders' equity [2] - The company sees the issuance of convertible bonds as an opportunity to expand and strengthen its capital base while attracting new investors to broaden its shareholder base [2]

Core Viewpoint - China Biotechnology Services (08037) has entered into a subscription agreement with Fucai Holdings to issue convertible bonds worth $35 million, equivalent to approximately HKD 272.3 million, aimed at strengthening the company's capital base and financial position [1] Group 1: Convertible Bonds Issuance - The company has conditionally agreed to issue convertible bonds with a principal amount of $35 million [1] - The initial conversion price is set at HKD 0.66 per share, which is subject to adjustment [1] - If the conversion rights attached to the bonds are fully exercised, up to 412.6 million shares will be issued, representing approximately 42.28% of the total shares currently in issue [1] Group 2: Impact on Shareholders - The issuance of convertible bonds will not cause immediate dilution of existing shareholders' equity [1] - If the conversion rights are exercised, the total number of shares issued will increase by approximately 29.72%, assuming no changes in the company's issued share capital from the announcement date until conversion [1] Group 3: Investor Profile - The subscriber, Fucai Holdings, primarily engages in investment activities across various sectors, including life sciences, education, internet, technology media, and telecommunications, managing assets exceeding $100 million [1] Group 4: Strategic Rationale - The board believes that the subscription will enhance the company's capital foundation, preparing for long-term development and improving financial conditions [1] - The issuance of convertible bonds is seen as an opportunity to expand and strengthen the capital base while attracting new investors to broaden the shareholder base [1]